Atai Life Sciences N.V. Q1 FY2022 Earnings Call

· Earnings call transcript and AI-powered summary

  • Cash Position: Ended Q1 2022 with $335 million in cash, with $27 million used during the quarter. Management reiterated sufficient runway into 2024.
  • Expenses: Total R&D and G&A expenses were in line with expectations, emphasizing disciplined cash management.
  • Biotech Market Context: CEO Florian Brand highlighted undervaluation in biotech, with companies trading near or below cash. atai is positioned to take advantage of these market conditions.
  • Therapeutic Focus: Targets unmet needs in neuropsychiatry where only 17 drugs have been approved since 2015, versus 108 in oncology.
  • Digital Therapeutics: Integral to atai's treatment approach and fully funded. Combined with compounds to enhance durable therapeutic effects. Digital programs are lower risk than drug assets and contribute to capital efficiency.

Pipeline Updates

  • PCN-101 (R-ketamine): Targeted for at-home use, differentiated from Janssen's SPRAVATO (esketamine). Leverages over 1,000 licensed treatment clinics in the U.S. PCN-101 aims to slot into existing clinical infrastructure established by SPRAVATO’s rollout.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Greg Weaver: Hi everyone, I’m Greg Weaver, CFO of atai Life Sciences. And I’m pleased to welcome you to our First Quarter 2022 Earnings Management Interview. I’m joined today by my colleagues, CEO, Florian Brand; and CSO, Srini Rao. We thought we do things a bit differently this time by hosting a conversation with two of our analysts, Charles Duncan from Cantor, and Ritu Baral from Cowen and we’re super excited to have them here with us today. Over the next 30 minutes Ritu and Charles will be asking us a series of questions on our Q1 activities and progress made in our pipeline developments. As a reminder, our discussion today may include forward-looking statements about atai’s future results and performance, which are subject to risks and uncertainties that may cause actual results to differ. atai does not undertake any obligation to update such statements, which speak only as of today. Before moving to the interview, I’d like to briefly comment on our first quarter cash and operating expenses as reported in today’s Q1 earnings release. Our first quarter use of cash, total operating expenses, R&D and G&A expenses were generally in line with expectations. The total use of cash of $27 million for the quarter and we ended the Q1 with $335 million in cash. And we reiterate our guidance with runway into 2024. I’d like to emphasize the strength of that cash position with liquidity on hand to reach multiple key clinical milestones over the next two years and with our continued disc

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional